InfiCure Bio is a renowned life science company that specializes in offering unique preclinical models and services for the study of inflammation and fibrosis. Their flagship preclinical model, the NIF mouse, is a groundbreaking tool for testing anti-fibrotic drugs. What sets the NIF mouse apart is its spontaneous development of fibrosis, seen in multiple organs like the liver and kidney, and its ability to mimic the chronic inflammation found in various human conditions.

This makes it highly relevant for studying and developing therapies for chronic liver disease, chronic kidney disease, and more. InfiCure Bio's business model revolves around collaborating with pharmaceutical companies and providing them with comprehensive services for testing their anti-inflammatory/anti-fibrotic drugs in the unique preclinical model. They offer support in all aspects, from experimental set-up to execution, analysis, and reporting of results.

The NIF mouse model offers several advantages, including early onset leading to shortened test protocols and 100% reproducibility of the fibrosis phenotype. Led by a team of experienced professionals, including the CEO Sofia Mayans and CSO Dan Holmberg, InfiCure Bio has created a niche for itself in the field of inflammation and fibrosis research. Their expertise, combined with their dedication to privacy and confidentiality, ensures that they handle sensitive data with the utmost care.

If you're looking for a partner in developing innovative therapies for inflammation and fibrosis, InfiCure Bio is your go-to choice